- Home
- Publications
- Publication Search
- Publication Details
Title
FLT3 inhibitor quizartinib (AC220)
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume -, Issue -, Pages 1-11
Publisher
Informa UK Limited
Online
2019-04-18
DOI
10.1080/10428194.2019.1602263
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
- (2018) Jorge Cortes et al. LANCET ONCOLOGY
- Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
- (2017) Masamichi Mori et al. INVESTIGATIONAL NEW DRUGS
- Impaired von Willebrand factor adhesion and platelet response in thrombospondin-2 knockout mice
- (2016) N. Kristofik et al. BLOOD
- Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis
- (2016) Abhinav Deol et al. CANCER
- Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia
- (2015) Tapan Kadia et al. BRITISH JOURNAL OF HAEMATOLOGY
- Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia
- (2015) I-K Park et al. LEUKEMIA
- FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
- (2015) C C Smith et al. LEUKEMIA
- Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?
- (2015) Melanie Janning et al. Expert Review of Hematology
- Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397
- (2015) C. C. Smith et al. Cancer Discovery
- Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification
- (2015) Yi-Yu Ke et al. Scientific Reports
- Crystal Structure of the FLT3 Kinase Domain Bound to the Inhibitor Quizartinib (AC220)
- (2015) Julie A. Zorn et al. PLoS One
- Treatment with FLT3 inhibitor in patients withFLT3-mutated acute myeloid leukemia is associated with development of secondaryFLT3-tyrosine kinase domain mutations
- (2014) Yesid Alvarado et al. CANCER
- Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies
- (2014) W. Zhang et al. CLINICAL CANCER RESEARCH
- Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma
- (2013) I. Ben-Batalla et al. BLOOD
- Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia
- (2013) E. I. Zimmerman et al. BLOOD
- Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target
- (2013) I.-K. Park et al. BLOOD
- Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival
- (2013) A. K. Burnett et al. BLOOD
- Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase
- (2013) Xiaochuan Yang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status
- (2013) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Diversity of the juxtamembrane and TKD1 mutations (Exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data
- (2012) Susanne Schnittger et al. GENES CHROMOSOMES & CANCER
- Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis
- (2012) Salut Brunet et al. JOURNAL OF CLINICAL ONCOLOGY
- Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
- (2012) A S Moore et al. LEUKEMIA
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
- (2012) Catherine C. Smith et al. NATURE
- Role of Allogeneic Transplantation for FLT3/ITD Acute Myeloid Leukemia: Outcomes from 133 Consecutive Newly Diagnosed Patients from a Single Institution
- (2011) Amy E. DeZern et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1 -mediated down-regulation of CXCL12
- (2011) K. Kojima et al. BLOOD
- FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
- (2011) T. Sato et al. BLOOD
- Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors
- (2011) A. Parmar et al. CANCER RESEARCH
- A potential therapeutic target for FLT3-ITD AML: PIM1 kinase
- (2011) Amir T. Fathi et al. LEUKEMIA RESEARCH
- FLT3 as a therapeutic target in AML: still challenging after all these years
- (2010) T. Kindler et al. BLOOD
- Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
- (2010) D. Grimwade et al. BLOOD
- FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
- (2009) K. W. Pratz et al. BLOOD
- Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome
- (2009) S. Kayser et al. BLOOD
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
- (2009) P. P. Zarrinkar et al. BLOOD
- FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro
- (2009) N. von Bubnoff et al. CANCER RESEARCH
- Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
- (2009) Elaine R. Mardis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells
- (2008) E. Weisberg et al. BLOOD
- Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
- (2008) Z. Zeng et al. BLOOD
- Molecular characterization of acute myeloid leukemia
- (2008) K. Dohner et al. HAEMATOLOGICA
- Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia
- (2008) S. Hu et al. MOLECULAR CANCER THERAPEUTICS
- Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
- (2008) Richard F. Schlenk et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More